Tango Therapeutics(TNGX.US) 10% Shareholder Sells US$5.39 Million in Common Stock

$Tango Therapeutics(TNGX.US)$ 10% Shareholder Third Rock Ventures IV, L.P. sold 550.17K shares of common stock on Jul 17, 2024 at an average price of $9.7903 for a total value of $5.39 million. This

Moomoo NewsJul 18 16:19 ET

Form 144 | Tango Therapeutics(TNGX.US) Insider Proposes to Sell 5.37 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Jul 17, $Tango Therapeutics(TNGX.US)$ Insider Third Rock Ventures IV, L.P. intends to sell 550.17K shares of its common stock on Jul 17, with a total market value of

Moomoo NewsJul 17 17:33 ET

Jefferies Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $19

Jefferies analyst Maury Raycroft initiates coverage on $Tango Therapeutics(TNGX.US)$ with a buy rating, and sets the target price at $19.According to TipRanks data, the analyst has a success rate of 4

Moomoo NewsJul 17 12:31 ET · Ratings

Tango Therapeutics: Promising Market Prospects With Novel MTAP Deletion Cancer Therapies

TipRanksJul 17 12:25 ET

Tango Therapeutics Price Target Announced at $19.00/Share by Jefferies

Tango Therapeutics Price Target Announced at $19.00/Share by

Dow JonesJul 17 08:56 ET

Jefferies Initiates Tango Therapeutics at Buy With $19 Price Target

Tango Therapeutics (TNGX) has average rating of buy and price targets ranging from $11 to $19, according to analysts polled by Capital IQ.Price: 9.87, Change: +0.03, Percent Change: +0.30

MT NewswiresJul 17 08:16 ET